Supply Chain Archives

10/08/2025
Resilience by Design: Lessons from Real-World Disruption
When it comes to Advanced Therapy Medicinal Products (ATMPs), disruption isn’t an “if,” it’s a “when.” When you’re dealing with unpredictable situations like geopolitical instability, sudden site closures, supply chain bottlenecks, or even weather-related delays, any disruption can potentially jeopardize patient treatments that may be irreplaceable. For sensitive therapies like these with narrow viability windows and strict temperature requirements, even a small deviation in process can have outsized consequences. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, explained why resilience is one of the most critical (but often overlooked) pillars of ATMP delivery.
09/15/2025
What’s Slowing the Journey from Therapy to Patient? Inside the Operational Hurdles of ATMPs
As more advanced therapy medicinal products (ATMPs) move from clinical trials to commercial launch, the industry has reached a critical inflection point. The science is advancing, approvals are accelerating, but patients still face steep barriers to access. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, outlined the operational realities that stand between innovation and patient benefit. These challenges span manufacturing capacity, cold chain infrastructure, site coordination, and regional complexity.
08/25/2025
What’s Next for ATMP Regulation in EMEA
For advanced therapy developers expanding into Europe, regulatory approval is just the beginning. Even after securing authorization from the European Medicines Agency (EMA), companies often find themselves mired in a patchwork of national rules, pricing hurdles, and even access delays. In her recent appearance on the Beyond Biotech podcast by Labiotech, Alison Pritchard, Vice President of Business Development for Cryoport Systems in EMEA, pulled back the curtain on what it really takes to bring advanced therapies to patients across the region.
08/04/2025
ATMP Development in 2025: Promise, Pressure, and the Push to Scale
As the advanced therapy medicinal products (ATMP) sector reaches the midpoint of 2025, there’s no shortage of scientific momentum. Groundbreaking CRISPR-based therapies are making headlines. Patient access to cell and gene therapies is expanding beyond early adopter markets. And a maturing global regulatory environment is slowly but surely creating new opportunities for commercialization. But alongside this promise comes pressure.Categories
- All (61)
- Industry Insights (18)
- Managing the Cold Chain (37)
- Navigating Logistics (24)
- Patient Access and Awareness (8)
Tags
- Asia
- ATMPs
- Biologics
- BioServices
- Biostorage
- CDMOs
- Cell Therapy
- Clinical Trials
- Cold Chain Management
- Commercialization
- CROs
- Cryopreservation
- Europe
- Fragmentation
- Gene Therapy
- Global Logistics Tracking
- Global Supply Chain Management
- International Shipping
- North America
- Risk Mitigation
- Standards and Compliance
- Supply Chain Management